Login Register Cart 0
Generic placeholder image

Current Alzheimer Research

Editor-in-Chief

ISSN (Print): 1567-2050
ISSN (Online): 1875-5828

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe Translate in Chinese
Meta-Analysis

Blood Neurofilament Light Chain in Different Types of Dementia

Author(s): Lihua Gu, Hao Shu, Yanjuan Wang and Pan Wang*

Volume 20, Issue 3, 2023

Published on: 23 June, 2023

Page: [149 - 160] Pages: 12

DOI: 10.2174/1567205020666230601123123

Price: $65

Abstract

Aims: The study aimed to evaluate diagnostic values of circulating neurofilament light chain (NFL) levels in different types of dementia.

Background: Previous studies reported inconsistent change of blood NFL for different types of dementia, including Alzheimer’s disease (AD), frontotemporal dementia (FTD), Parkinson’s disease dementia (PDD) and Creutzfeldt-Jakob disease (CJD) and Lewy body dementia (LBD).

Objective: Meta-analysis was conducted to summarize the results of studies evaluating diagnostic values of circulating NFL levels in different types of dementia to enhance the strength of evidence.

Methods: Articles evaluating change in blood NFL levels in dementia and published before July 2022 were searched on the following databases (PubMed, Web of Science, EMBASE, Medline and Google Scholar). The computed results were obtained by using STATA 12.0 software.

Results: AD patients showed increased NFL concentrations in serum and plasma, compared to healthy controls (HC) (standard mean difference (SMD) = 1.09, 95% confidence interval (CI): 0.48, 1.70, I2 = 97.4%, p < 0.001). In AD patients, higher NFL concentrations in serum and plasma were associated with reduced cerebrospinal fluid (CSF) Aβ1-42, increased CSF t-tau, increased CSF p-tau, reduced Mini-Mental State Examination (MMSE) and decreased memory. Additionally, mild cognitive impairment (MCI) showed elevated NFL concentrations in serum and plasma, compared to HC (SMD = 0.53, 95% CI: 0.18, 0.87, I2 = 93.8%, p < 0.001). However, in MCI, no significant association was found between NFL concentrations in serum, plasma and memory or visuospatial function. No significant difference was found between preclinical AD and HC (SMD = 0.18, 95% CI: -0.10, 0.47, I2 = 0.0%, p = 0.438). FTD patients showed increased NFL concentrations in serum and plasma, compared to HC (SMD = 1.08, 95% CI: 0.72, 1.43, I2 = 83.3%, p < 0.001). Higher NFL concentrations in serum and plasma were associated with increased CSF NFL in FTD. Additionally, the pooled parameters calculated were as follows: sensitivity, 0.82 (95% CI: 0.72, 0.90); specificity, 0.91 (95% CI: 0.83, 0.96). CJD patients showed increased NFL concentrations in serum and plasma, compared to HC. No significant difference in NFL level in serum and plasma was shown between AD and FTD (SMD = -0.03, 95% CI: -0.77, 0.72, I2 = 83.3%, p = 0.003).

Conclusion: In conclusion, the study suggested abnormal blood NFL level in AD and MCI, but not in preclinical AD. FTD and CJD showed abnormal blood NFL levels.

Keywords: Dementia, neurofilament light chain, plasma, serum, meta-analysis, neurodegeneration.

« Previous Next »
[1]
Khalil, M.; Teunissen, C.E.; Otto, M. Neurofilaments as biomarkers in neurological disorders. Nature Rev. Neurol., 2018, 14, 577-589.
[2]
Meeker, K.L.; Butt, O.H.; Gordon, B.A.; Fagan, A.M.; Schindler, S.E.; Morris, J.C.; Benzinger, T.L.S.; Ances, B.M. Cerebrospinal fluid neurofilament light chain is a marker of aging and white matter damage. Neurobiol. Dis., 2022, 166, 105662.
[http://dx.doi.org/10.1016/j.nbd.2022.105662] [PMID: 35167933]
[3]
Gaiottino, J.; Norgren, N.; Dobson, R.; Topping, J.; Nissim, A.; Malaspina, A.; Bestwick, J.P.; Monsch, A.U.; Regeniter, A.; Lindberg, R.L.; Kappos, L.; Leppert, D.; Petzold, A.; Giovannoni, G.; Kuhle, J. Increased neurofilament light chain blood levels in neurodegenerative neurological diseases. PLoS One, 2013, 8(9), e75091.
[http://dx.doi.org/10.1371/journal.pone.0075091] [PMID: 24073237]
[4]
Rohrer, J.D.; Woollacott, I.O.C.; Dick, K.M.; Brotherhood, E.; Gordon, E.; Fellows, A.; Toombs, J.; Druyeh, R.; Cardoso, M.J.; Ourselin, S.; Nicholas, J.M.; Norgren, N.; Mead, S.; Andreasson, U.; Blennow, K.; Schott, J.M.; Fox, N.C.; Warren, J.D.; Zetterberg, H. Serum neurofilament light chain protein is a measure of disease intensity in frontotemporal dementia. Neurology, 2016, 87(13), 1329-1336.
[http://dx.doi.org/10.1212/WNL.0000000000003154] [PMID: 27581216]
[5]
Lin, Y.S.; Lee, W.J.; Wang, S.J.; Fuh, J.L. Levels of plasma neurofilament light chain and cognitive function in patients with Alzheimer or Parkinson disease. Sci. Rep., 2018, 8(1), 17368.
[6]
Thompson, A.G.B.; Luk, C.; Heslegrave, A.J.; Zetterberg, H.; Mead, S.H.; Collinge, J.; Jackson, G.S. Neurofilament light chain and tau concentrations are markedly increased in the serum of patients with sporadic Creutzfeldt-Jakob disease, and tau correlates with rate of disease progression. J. Neurol. Neurosurg. Psychiatry, 2018, 89(9), 955-961.
[http://dx.doi.org/10.1136/jnnp-2017-317793] [PMID: 29487167]
[7]
Steinacker, P.; Anderl-Straub, S.; Diehl-Schmid, J.; Semler, E.; Uttner, I.; von Arnim, C.A.F.; Barthel, H.; Danek, A.; Fassbender, K.; Fliessbach, K.; Foerstl, H.; Grimmer, T.; Huppertz, H.J.; Jahn, H.; Kassubek, J.; Kornhuber, J.; Landwehrmeyer, B.; Lauer, M.; Maler, J.M.; Mayer, B.; Oeckl, P.; Prudlo, J.; Schneider, A.; Volk, A.E.; Wiltfang, J.; Schroeter, M.L.; Ludolph, A.C.; Otto, M. Serum neurofilament light chain in behavioral variant frontotemporal dementia. Neurology, 2018, 91(15), e1390-e1401.
[http://dx.doi.org/10.1212/WNL.0000000000006318] [PMID: 30209235]
[8]
Moher, D.; Liberati, A.; Tetzlaff, J.; Altman, D.G. preferred reporting items for systematic reviews and meta-analyses: The prisma statement. Int. J. Surg., 2010, 8(5), 336-341.
[9]
Weston, P.S.J.; Poole, T.; Ryan, N.S.; Nair, A.; Liang, Y.; Macpherson, K.; Druyeh, R.; Malone, I.B.; Ahsan, R.L.; Pemberton, H.; Klimova, J.; Mead, S.; Blennow, K.; Rossor, M.N.; Schott, J.M.; Zetterberg, H.; Fox, N.C. Serum neurofilament light in familial Alzheimer disease. Neurology, 2017, 89(21), 2167-2175.
[http://dx.doi.org/10.1212/WNL.0000000000004667] [PMID: 29070659]
[10]
Bartos, A.; Fialová, L.; Švarcová, J. Lower serum antibodies against tau protein and heavy neurofilament in Alzheimer’s disease. J. Alzheimers Dis., 2018, 64(3), 751-760.
[http://dx.doi.org/10.3233/JAD-180039] [PMID: 29966192]
[11]
Denk, J.; Oberhauser, F.; Kornhuber, J.; Wiltfang, J.; Fassbender, K.; Schroeter, M.L.; Volk, A.E.; Diehl-Schmid, J.; Prudlo, J.; Danek, A.; Landwehrmeyer, B.; Lauer, M.; Otto, M.; Jahn, H. Specific serum and CSF microRNA profiles distinguish sporadic behavioural variant of frontotemporal dementia compared with Alzheimer patients and cognitively healthy controls. PLoS One, 2018, 13(5), e0197329.
[http://dx.doi.org/10.1371/journal.pone.0197329] [PMID: 29746584]
[12]
Sánchez-Valle, R.; Heslegrave, A.; Foiani, M.S.; Bosch, B.; Antonell, A.; Balasa, M.; Lladó, A.; Zetterberg, H.; Fox, N.C. Serum neurofilament light levels correlate with severity measures and neurodegeneration markers in autosomal dominant Alzheimer’s disease. Alzheimers Res. Ther., 2018, 10(1), 113.
[http://dx.doi.org/10.1186/s13195-018-0439-y] [PMID: 30390718]
[13]
Weston, P.S.J.; Poole, T.; O’Connor, A.; Heslegrave, A.; Ryan, N.S.; Liang, Y.; Druyeh, R.; Mead, S.; Blennow, K.; Schott, J.M.; Frost, C.; Zetterberg, H.; Fox, N.C. Longitudinal measurement of serum neurofilament light in presymptomatic familial Alzheimer’s disease. Alzheimers Res. Ther., 2019, 11(1), 19.
[http://dx.doi.org/10.1186/s13195-019-0472-5] [PMID: 30786919]
[14]
Ashton, N.J.; Leuzy, A.; Lim, Y.M.; Troakes, C.; Hortobágyi, T.; Höglund, K.; Aarsland, D.; Lovestone, S.; Schöll, M.; Blennow, K.; Zetterberg, H.; Hye, A. Increased plasma neurofilament light chain concentration correlates with severity of post-mortem neurofibrillary tangle pathology and neurodegeneration. Acta Neuropathol. Commun., 2019, 7(1), 5.
[http://dx.doi.org/10.1186/s40478-018-0649-3] [PMID: 30626432]
[15]
Kovacs, G.G.; Andreasson, U.; Liman, V.; Regelsberger, G.; Lutz, M.I.; Danics, K.; Keller, E.; Zetterberg, H.; Blennow, K. Plasma and cerebrospinal fluid tau and neurofilament concentrations in rapidly progressive neurological syndromes: A neuropathology-based cohort. Eur. J. Neurol., 2017, 24(11), 1326-e77.
[http://dx.doi.org/10.1111/ene.13389] [PMID: 28816001]
[16]
Lewczuk, P.; Ermann, N.; Andreasson, U.; Schultheis, C.; Podhorna, J.; Spitzer, P.; Maler, J.M.; Kornhuber, J.; Blennow, K.; Zetterberg, H. Plasma neurofilament light as a potential biomarker of neurodegeneration in Alzheimer’s disease. Alzheimers Res. Ther., 2018, 10(1), 71.
[http://dx.doi.org/10.1186/s13195-018-0404-9] [PMID: 30055655]
[17]
Matías-Guiu, J.A.; Gómez-Pinedo, U.; Forero, L.; Pytel, V.; Cano, F.; Moreno-Ramos, T.; Cabrera-Martín, M.N.; Matías-Guiu, J.; González-Rosa, J.J. Plasma neurofilament light chain in primary progressive aphasia and related disorders: Clinical significance and metabolic correlates. J. Alzheimers Dis., 2019, 72(3), 773-782.
[http://dx.doi.org/10.3233/JAD-190838] [PMID: 31640103]
[18]
Mattsson, N.; Andreasson, U.; Zetterberg, H.; Blennow, K. Association of plasma neurofilament light with neurodegeneration in patients with Alzheimer disease. JAMA Neurol., 2017, 74(5), 557-566.
[http://dx.doi.org/10.1001/jamaneurol.2016.6117] [PMID: 28346578]
[19]
Mattsson, N.; Cullen, N.C.; Andreasson, U.; Zetterberg, H.; Blennow, K. Association between longitudinal plasma neurofilament light and neurodegeneration in patients with alzheimer disease. JAMA Neurol., 2019, 76(7), 791-799.
[http://dx.doi.org/10.1001/jamaneurol.2019.0765] [PMID: 31009028]
[20]
Pereira, J.B.; Westman, E.; Hansson, O. Association between cerebrospinal fluid and plasma neurodegeneration biomarkers with brain atrophy in Alzheimer’s disease. Neurobiol. Aging, 2017, 58, 14-29.
[http://dx.doi.org/10.1016/j.neurobiolaging.2017.06.002] [PMID: 28692877]
[21]
Startin, C.M.; Ashton, N.J.; Hamburg, S.; Hithersay, R.; Wiseman, F.K.; Mok, K.Y.; Hardy, J.; Lleó, A.; Lovestone, S.; Parnetti, L.; Zetterberg, H.; Hye, A.; Strydom, A. Plasma biomarkers for amyloid, tau, and cytokines in Down syndrome and sporadic Alzheimer’s disease. Alzheimers Res. Ther., 2019, 11(1), 26.
[http://dx.doi.org/10.1186/s13195-019-0477-0] [PMID: 30902060]
[22]
Zhou, W.; Zhang, J.; Ye, F.; Xu, G.; Su, H.; Su, Y.; Zhang, X. Plasma neurofilament light chain levels in Alzheimer’s disease. Neurosci. Lett., 2017, 650, 60-64.
[http://dx.doi.org/10.1016/j.neulet.2017.04.027] [PMID: 28428015]
[23]
Mielke, M.M.; Syrjanen, J.A.; Blennow, K.; Zetterberg, H.; Vemuri, P.; Skoog, I.; Machulda, M.M.; Kremers, W.K.; Knopman, D.S.; Jack, C., Jr; Petersen, R.C.; Kern, S. Plasma and CSF neurofilament light. Neurology, 2019, 93(3), e252-e260.
[http://dx.doi.org/10.1212/WNL.0000000000007767] [PMID: 31182505]
[24]
Palmqvist, S.; Janelidze, S.; Stomrud, E.; Zetterberg, H.; Karl, J.; Zink, K.; Bittner, T.; Mattsson, N.; Eichenlaub, U.; Blennow, K.; Hansson, O. Performance of fully automated plasma assays as screening tests for alzheimer disease–related β-Amyloid status. JAMA Neurol., 2019, 76(9), 1060-1069.
[http://dx.doi.org/10.1001/jamaneurol.2019.1632] [PMID: 31233127]
[25]
Shi, Y.; Lu, X.; Zhang, L.; Shu, H.; Gu, L.; Wang, Z. Potential value of plasma amyloid-beta, total tau, and neurofilament light for identification of early Alzheimer’s Disease. ACS Chem. Neurosci., 2019, 10(8), 3479-3485.
[26]
Chatterjee, P.; Goozee, K.; Sohrabi, H.R.; Shen, K.; Shah, T.; Asih, P.R.; Dave, P.; ManYan, C.; Taddei, K.; Chung, R.; Zetterberg, H.; Blennow, K.; Martins, R.N. Association of plasma neurofilament light chain with neocortical Amyloid-β load and cognitive performance in cognitively normal elderly participants. J. Alzheimers Dis., 2018, 63(2), 479-487.
[http://dx.doi.org/10.3233/JAD-180025] [PMID: 29630554]
[27]
Meeter, L.H.; Dopper, E.G.; Jiskoot, L.C.; Sanchez-Valle, R.; Graff, C.; Benussi, L.; Ghidoni, R.; Pijnenburg, Y.A.; Borroni, B.; Galimberti, D.; Laforce, R.J.; Masellis, M.; Vandenberghe, R.; Ber, I.L.; Otto, M.; van Minkelen, R.; Papma, J.M.; Rombouts, S.A.; Balasa, M.; Öijerstedt, L.; Jelic, V.; Dick, K.M.; Cash, D.M.; Harding, S.R.; Jorge Cardoso, M.; Ourselin, S.; Rossor, M.N.; Padovani, A.; Scarpini, E.; Fenoglio, C.; Tartaglia, M.C.; Lamari, F.; Barro, C.; Kuhle, J.; Rohrer, J.D.; Teunissen, C.E.; van Swieten, J.C. Neurofilament light chain: A biomarker for genetic frontotemporal dementia. Ann. Clin. Transl. Neurol., 2016, 3(8), 623-636.
[http://dx.doi.org/10.1002/acn3.325] [PMID: 27606344]
[28]
Wilke, C.; Preische, O.; Deuschle, C.; Roeben, B.; Apel, A.; Barro, C.; Maia, L.; Maetzler, W.; Kuhle, J.; Synofzik, M. Neurofilament light chain in FTD is elevated not only in cerebrospinal fluid, but also in serum. J. Neurol. Neurosurg. Psychiatry, 2016, 87(11), 1270-1272.
[http://dx.doi.org/10.1136/jnnp-2015-312972] [PMID: 27188986]
[29]
van der Ende, E.L.; Meeter, L.H.; Poos, J.M.; Panman, J.L.; Jiskoot, L.C.; Dopper, E.G.P.; Papma, J.M.; de Jong, F.J.; Verberk, I.M.W.; Teunissen, C.; Rizopoulos, D.; Heller, C.; Convery, R.S.; Moore, K.M.; Bocchetta, M.; Neason, M.; Cash, D.M.; Borroni, B.; Galimberti, D.; Sanchez-Valle, R.; Laforce, R., Jr; Moreno, F.; Synofzik, M.; Graff, C.; Masellis, M.; Carmela Tartaglia, M.; Rowe, J.B.; Vandenberghe, R.; Finger, E.; Tagliavini, F.; de Mendonça, A.; Santana, I.; Butler, C.; Ducharme, S.; Gerhard, A.; Danek, A.; Levin, J.; Otto, M.; Frisoni, G.B.; Cappa, S.; Pijnenburg, Y.A.L.; Rohrer, J.D.; van Swieten, J.C.; Rossor, M.N.; Warren, J.D.; Fox, N.C.; Woollacott, I.O.C.; Shafei, R.; Greaves, C.; Guerreiro, R.; Bras, J.; Thomas, D.L.; Nicholas, J.; Mead, S.; van Minkelen, R.; Barandiaran, M.; Indakoetxea, B.; Gabilondo, A.; Tainta, M.; de Arriba, M.; Gorostidi, A.; Zulaica, M.; Villanua, J.; Diaz, Z.; Borrego-Ecija, S.; Olives, J.; Lladó, A.; Balasa, M.; Antonell, A.; Bargallo, N.; Premi, E.; Cosseddu, M.; Gazzina, S.; Padovani, A.; Gasparotti, R.; Archetti, S.; Black, S.; Mitchell, S.; Rogaeva, E.; Freedman, M.; Keren, R.; Tang-Wai, D.; Öijerstedt, L.; Andersson, C.; Jelic, V.; Thonberg, H.; Arighi, A.; Fenoglio, C.; Scarpini, E.; Fumagalli, G.; Cope, T.; Timberlake, C.; Rittman, T.; Shoesmith, C.; Bartha, R.; Rademakers, R.; Wilke, C.; Karnath, H-O.; Bender, B.; Bruffaerts, R.; Vandamme, P.; Vandenbulcke, M.; Ferreira, C.B.; Miltenberger, G.; Maruta, C.; Verdelho, A.; Afonso, S.; Taipa, R.; Caroppo, P.; Di Fede, G.; Giaccone, G.; Prioni, S.; Redaelli, V.; Rossi, G.; Tiraboschi, P.; Duro, D.; Rosario Almeida, M.; Castelo-Branco, M.; João Leitão, M.; Tabuas-Pereira, M.; Santiago, B.; Gauthier, S.; Schonecker, S.; Semler, E.; Anderl-Straub, S.; Benussi, L.; Binetti, G.; Ghidoni, R.; Pievani, M.; Lombardi, G.; Nacmias, B.; Ferrari, C.; Bessi, V. Serum neurofilament light chain in genetic frontotemporal dementia: a longitudinal, multicentre cohort study. Lancet Neurol., 2019, 18(12), 1103-1111.
[http://dx.doi.org/10.1016/S1474-4422(19)30354-0] [PMID: 31701893]
[30]
Heller, C.; Foiani, M.S. Plasma glial fibrillary acidic protein is raised in progranulin-associated frontotemporal dementia. J. Neurol. Neurosurg. Psychiatry, 2020, 91(3), 263-270.
[31]
Steinacker, P.; Blennow, K.; Halbgebauer, S.; Shi, S.; Ruf, V.; Oeckl, P.; Giese, A.; Kuhle, J.; Slivarichova, D.; Zetterberg, H.; Otto, M. Neurofilaments in blood and CSF for diagnosis and prediction of onset in Creutzfeldt-Jakob disease. Sci. Rep., 2016, 6(1), 38737.
[http://dx.doi.org/10.1038/srep38737] [PMID: 27929120]
[32]
Pilotto, A.; Imarisio, A.; Carrarini, C.; Russo, M.; Masciocchi, S.; Gipponi, S.; Cottini, E.; Aarsland, D.; Zetterberg, H.; Ashton, N.J.; Hye, A.; Bonanni, L.; Padovani, A. Plasma neurofilament light chain predicts cognitive progression in prodromal and clinical dementia with lewy bodies. J. Alzheimers Dis., 2021, 82(3), 913-919.
[http://dx.doi.org/10.3233/JAD-210342] [PMID: 34151807]
[33]
Jin, M.; Cao, L.; Dai, Y. Role of neurofilament light chain as a potential biomarker for Alzheimer’s Disease: A correlative meta-analysis. Front. Aging Neurosci., 2019, 11, 254.
[http://dx.doi.org/10.3389/fnagi.2019.00254] [PMID: 31572170]
[34]
Forgrave, L.M.; Ma, M.; Best, J.R.; DeMarco, M.L. The diagnostic performance of neurofilament light chain in CSF and blood for Alzheimer’s disease, frontotemporal dementia, and amyotrophic lateral sclerosis: A systematic review and meta-analysis. Alzheimers Dement. (Amst)., 2019, 11, 730-743.
[http://dx.doi.org/10.1016/j.dadm.2019.08.009]

Rights & Permissions Print Cite
Article Metrics
66
3
Wayfinder Image
© 2024 Bentham Science Publishers | Privacy Policy